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Abstract. The benefit of postoperative adjuvant chemotherapy
in patients with Dukes' B colorectal cancer is still uncertain
and its routine use is not recommended. The five-year relapse
rate is ~25-40% and the identification of patients at high risk
of recurrence would represent an important strategy for the
use of adjuvant chemotherapy. We retrospectively analyzed
gene expression profiles in frozen tumor specimens from
patients with Dukes' B colorectal cancer by using high density
oligonucleotide microarrays. Our results show a subset of 48
genes differentially expressed with an associated probability
<0.001 in the t-test. Another statistical procedure based on
the Fisher criterion resulted in 11 genes able to separate both
groups. We selected the 8 genes present in both subsets. The
differential expression of five genes (CHD2, RPS5, ZNF148,
BRI3 and MGC23401) in colon cancer progression was
confirmed by real-time PCR in an independent set of patients
of Dukes' B and C stages.
Introduction
Colorectal cancer (CRC) is one of the major causes of cancer
death worldwide (1). To date, radical surgery followed by
adjuvant chemotherapy in patients with node-positive disease
(Dukes' C stage), is the mainstay of therapy (2). In the node-
negative Dukes' B stage disease no adjuvant chemotherapy is
used after tumor resection, although 25-40% of patients will
develop recurrent disease; therefore, the role of adjuvant
chemotherapy in this setting is still unclear (3). Although the
pathological TNM (tumor-node-metastasis) staging system
represents the main tool for identifying prognostic
differences (4), this system is not sufficient for predicting
recurrence in Dukes' B stage (5). There is a need to identify
predictive factors, in addition to TNM staging, to guide the
identification of Dukes' B patients that are likely to relapse.
This would be of great help in improving treatment strategies
in the node-negative disease.
In this regard, several molecules have been proposed as
predictive markers for colorectal cancer relapse; however,
data for most markers remain inconclusive (6). Thus, there are
technological limitations for accurately predicting recurrence
by traditional methods. High inter-patient heterogeneity of
colorectal carcinoma can also limit the predictive ability of
tests.
The development of microarray technologies, which allow
parallel analyses of many genes, has led to a new era in
medical science (7). Several studies have demonstrated that
gene expression signatures could predict clinical outcome (8).
In colorectal cancer, a study using Affimetrix technology
showed a 23-gene-set that represents a prognostic signature
inversely associated with a higher risk of tumor recurrence in
Dukes' B stage (9). In the present study, we report a gene
expression analysis of 16 patients with Dukes' B colon cancer
by using spotted microarrays containing 19000 oligo-
nucleotide sequences. Data analysis of microarrays is still a
matter of discussion among the scientific community. One of
the most worrying issues is the high risk of obtaining false
positives. In order to minimize this problem, we used two
different statistical procedures in the search of significant
differences of gene expression associated with relapse. Initially,
we used a permutation t-test for two means and secondly a
Fisher test with a variation of the ‘leave one out’ iteration
procedure, based on the study presented by Iizuka et al (10).
Only the genes selected by both procedures were considered
as differentially expressed between relapsed and non-relapsed
patients. We obtained a gene-set of 8 genes differentially
expressed between both groups.
Validation by real-time PCR was performed for those
genes whose probes hybridized with exon regions. We show
that down-regulation of BRI3, CHD2, MGC23401, ZNF148
and RPS5 genes is associated with colorectal cancer
progression.
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Patients and methods
Samples. This study includes 16 samples from Dukes' B
colorectal tumors which had undergone surgery at the
Department of Surgery of the University Clinic of Navarra,
between 1997 and 1999. None of the patients received adjuvant
chemotherapy or radiotherapy before surgery or after tumor
resection. Six patients developed recurrent disease and the
other 10 remained free of cancer 5 years after surgery. For con-
firmation of the association with recurrence and progression
of some genes obtained by gene expression profiling, we
analyzed the expression of five genes in an independent
prospective set of 27 samples with Dukes' B or C stage by
real-time PCR. All tumor samples were collected at resection
time and immediately frozen. Staging was performed according
to American Joint Committee on Cancer criteria (Greene, FL).
The ethics committee of the University Clinic of Navarra
approved this study and all patients gave their informed
consent.
DNA microarray analysis for gene expression profile.
Extraction of total RNA was performed with Trizol® total RNA
isolation reagent (Gibco BRL, Life Technologies, Gaitherburg,
MD, USA) according to the manufacturer's instructions. All the
RNA samples used in this study were cleaned up with RNeasy
mini kit (Quiagen, Valencia, CA) and were exhaustively
treated with RNase-free DNAse I (Quiagen) to remove residual
DNA. The concentration was quantified using RiboGreen
quantification kit (Molecular Probes, Leiden, The Netherlands)
and quality control of RNA was performed by electrophoresis
and ethidium bromide staining on a 2% agarose gel.
The corresponding cDNA probes were prepared using
the Micromax system (NEN, Perkin Elmer, Boston, MA)
according to the manufacturer's protocol. The labeled cDNA
was pre-heated to 50˚C and hybridized to Human 19K Oligo
array slides (60 mers) (Center for Applied Genomics,
University of Medicine of New Jersey).
After hybridization at 48˚C for 16 h in a slide cassette
(Telechem, Sunnyvale, CA), slides were washed sequentially
in a series of solutions of increasing stringency. Immediately
after washing, the presence of fluorescein-labeled cDNAs on
the microarray was detected using a fluorescent anti-fluorescein
antibody conjugate and TSA detection (Micromax) according
to the manufacturer's protocol with appropriate modifications.
Microarray data normalization and analysis. The GMS 418
scanner (Genetic Microsystems, Woburn, MA), a confocal
scanning instrument containing 2 laser sources and high-
resolution photo multiplier tubes (10 micron resolution) was
used for scanning the hybridized microarrays. After image
acquisition, the scanned images were imported into ImaGene
4.1 software (BioDiscovery, Marina del Re, CA) to quantify
the signal intensities.
The intensity value associated to each spot is the result
of subtracting a Gaussian function of the noise from the
foreground values (11). After this background subtraction,
base 2 logarithms of all data were calculated and genes with
more than two missing values were excluded from the analysis.
The remaining missing values were replaced by using the KNN
imputation method (12). Then, the quantile normalization
method (13) was applied to normalize the data.
The data discussed in this publication have been deposited
in NCBI's Gene Expression Omnibus (14) (GEO, http://www.
ncbi.nlm.nih.gov/geo/) and are accessible through GEO
Series accession number GSE2630.
We decided to use two different statistical procedures in
the search of significant differences in gene expression between
the two groups of patients. Only the genes selected by both
statistical procedures were considered as differentially
expressed between relapsed and non-relapsed patients. The
first test was a permutation t-test for comparison of two
means (15) and the second one a variation of the Fisher test
based on the work presented by Iizuka et al (10), in which
they searched for the optimal number of genes that could
differentiate between two groups of samples. Briefly, we used
the same algorithms for the calculation of the Fisher criterion,
then we tried different numbers of candidate genes and selected
30, a number that yielded very good classification results
when evaluated by means of Fast ICA (11) and Hierarchical
Clustering (17). The procedure consisted of selecting the 30
genes with the highest Fisher criterion value in 6 rounds of
iteration, each round leaving one sample of the relapsed group
and two of the non-relapsed group out of the calculations
(a variant of the ‘leave one out’ method). We selected the
genes present in at least 3 of the iterations.
In silico hybridizations. In order to confirm the identity of the
genes able to hybridize with the probes of the genetic signature,
we performed two in silico hybridizations with the sequence
of the human genome, one with the BLAT algorithm (18) of
the University of California Santa Cruz Genome Browser and
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Table I. Clinical and pathological characteristics of the




Characteristics Disease free Relapsed P-values
–––––––––––––––––––––––––––––––––––––––––––––––––
Age
Mean 64.4 62.7 0.77 (ns)
Sex
Female 4 1 0.34 (ns)
Male 6 5
T stage
2 3 3 1 (ns)
3 7 3
Tumor size




RC 3 1 0.81 (ns)
SC 6 4
–––––––––––––––––––––––––––––––––––––––––––––––––
aLC, left colon; RC, right colon; SC, colon-sigma; (ns), not significant.
–––––––––––––––––––––––––––––––––––––––––––––––––
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the other with the SSAHA algorithm (19) of the Ensemble
Genome Browser. We used the default parameters of both
algorithms.
In case of several possible hybridizations, we selected the
ones involving exons of well known genes, but in some cases
the only possible hybridization of the probes was with introns
or intergenic regions.
Real-time PCR. RNA extracted from an independent set of
27 patients (15 with Dukes' B and 12 with Dukes' C stage) was
used for confirmation of the results by real-time PCR. Total
RNA (2 μg) from each sample were used to generate cDNA
using the Taqman reverse transcription reagent kit (PE Applied
Biosystems, Foster City, CA). The reaction mixture was
incubated at 42˚C for 30 min, followed by incubation at 72˚C
for 10 min.
Each cDNA sample was analyzed in triplicate using the
ABI PRISM 7700 sequence detector (PE Applied Biosystems).
Real-time PCR was carried out using Taqman Universal PCR
master mix (Applied Biosystems), containing ROX to
normalize emissions. Primers and probes used for amplification
and detection of CHD2, BRI3, MGC23401, ZNF148 and 18S
ribosomal RNA were purchased from Applied Biosystems as
‘Assay on demand’ (Assay ID: Hs_00172280_m1, Assay ID:
Hs00854645_g1, Assay ID: Hs00299246_m1, Assay ID:
Hs00222661_m1 and Assay ID:Hs_99999907_m1). Primers
and Taqman probe for amplification and detection of RPS5
were designed using the Primer Express 1.0 software (Applied
Biosystems) (Forward: CTCATGACTGTGCGCATCGT,
Reverse: CACTGTTGATGATGGCGTTCA and Probe: TG
CCTTCGAGATCATACACCTGCTCACA). For thermal
cycling, the following conditions were applied: 10 min at
95˚C and 40 cycles of 15 sec at 95˚C and 1 min at 59˚C.
Expression levels were normalized to the Ct value of the
ribosomal RNA. Fold induction was calculated using the
formula 2-ΔCt, where ΔCt = target gene Ct-‘housekeeping’
gene Ct.
Results
Patient and tumor characteristics. Clinical and pathological
features of the patients and their tumors are summarized in
Table I. Information on age, gender, TNM stage, grade, tumor
size and tumor location were collected. The patient and tumor
characteristics did not differ significantly between relapsed and
non-relapsed patients.
Gene expression profile. Microarray technology was used to
analyze a series of 16 stage B colorectal tumors with different
outcome in terms of relapse. In order to identify gene markers
that can discriminate between the relapsed and the non-
relapsed patients, we performed a permutation t-test for
comparison of two means. Genes were selected regarding
their associated probability, considering 0.001 as the threshold
P-value for significant differences. According to this criterion,
48 genes are differentially expressed between relapsed and
non-relapsed patients. Further, we applied a variation of the
Fisher test. We tried different numbers of candidate genes and
selected 30 as an appropriate input for the selection procedure,
obtaining 11 genes that appeared in three or more iteration
rounds and yielded very good separation results when
evaluated by means of Fast ICA (Fig. 1) and unsupervised
Hierarchical Clustering (Fig. 2). Finally, we considered as a
good gene signature the genes selected by both statistical
procedures, a total of 8, 1 was up-regulated and 7 down-
regulated. This prognostic signature associates with a higher
risk of recurrence (Table II).
In silico hybridizations. In order to confirm the identity of the
genes able to hybridize with the eight probes, we performed
in silico hybridizations of the probes with the sequence of the
human genome, using the BLAT algorithm and the SSAHA
algorithm. By combination of the results of both algorithms
we assigned a unique hybridization site for each probe. Five
probes hybridized with exons of the genes chomodomain-
helicase DNA binding protein 2 (CHD2), ribosomal protein
S5 (RPS5), zinc finger DNA binding protein of 148 kDa
(ZNF148), brain protein I3 (BRI3) and the hypothetical protein
MGC23401. All these genes appear down-regulated in relapse
in our gene signature. Two other probes hybridize with introns
of two well known genes, H+ transporting lysosomal ATPase
V0 subunit A isoform 1 gene (ATP6V0A1) and ELK4, the
cofactor of the serum response factor. ATP6V0A1 is the only
gene in our gene signature that is up-regulated in relapse.
Finally, one probe hybridized only with the intergenic region
between the genes glucocorticoid modulatory element B1
(GMEB1) and high glucose regulated protein (HGRP8 or
YTHDF2).
Validation of microarray data by real-time PCR. In order to
confirm the role of these genes in CRC progression, we
measured the mRNA expression levels of 5 out of 8 genes
present in the putative prognostic signature (BRI3, ZNF148,
RPS5, MGC23401 and CHD2). RNA from an independent
set of patients was tested by real-time PCR. The results of PCR
analysis are in agreement with the microarray data (Fig. 3)
and confirm that this gene-set signature is associated with
colorectal cancer progression.
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Figure 1. Distribution of the samples according to the 11 gene-set
expression in an independent component analysis showed a clear separation
of two groups, corresponding exactly to the relapsed (right from the black
line) and non-relapsed (left) groups of patients.
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Discussion
The gold standard for predicting clinical outcome of most
cancers has been clinical and pathological staging of tumors
after surgery. However, patients with Dukes' B colorectal
cancer at the same tumor stages may show different outcome,
indicating that the conventional staging procedures may be
unable to precisely predict cancer prognosis. Therefore, the
search for new prognostic factors able to identify high-risk
patients and modulate cancer treatment options is still actively
BANDRÉS et al:  GENE SIGNATURE FOR DUKES' B COLON CANCER RECURRENCE PREDICTION1092
Figure 2. Unsupervised two-way hierarchical clustering with the 11 gene-set obtained by the variation of the Fisher test for 16 primary tumors of Dukes' B
colorectal cancer. Each row is a sample and each column is a gene.




NM_001271 Chromodomain helicase DNA binding, helicase activity,
DNA binding protein 2 (CHD2) regulation of transcription from Pol II promoter
NM_001009 Ribosomal protein S5 (RPS5) RNA binding
AF039019 Zinc finger protein 148 DNA binding, specific RNA
(ZNF148) polymerase II transcription factor activity
NM_015379 Brain protein I3 (BRI3) Involved in TNF· induced cell death
AF321617 ETS-domain protein ELK4 Transcription cofactor
AF086427 Unknown Unknown
AB011118 Hypothetical protein MGC23401 Unknown
AF085842 ATPase, H+ transporting, lysosomal V0 Cation transporter activity, 
subunit A isoform 1 (ATP6V01) hydrogen ion transporter activity
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aThe names of the probes are the GenBank accession numbers of the sequences used to design these probes. Names in bold correspond to
down-regulation in relapse, while underline indicates up-regulation in relapse.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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ongoing. Although many markers have been extensively
described, data for individual molecules failed to elaborate
the complex patterns of carcinogenesis and cancer
progression. In this regard, the development of microarray
technologies, that allow undertaking of parallel analyses of
many genes, could help to identify molecular factors involved
in cancer progression. In this study, we report an 8-gene
signature derived from microarray gene expression data with
the aim to identify molecular markers associated with relapse
in Dukes' B colon cancer patients. Our study suggests that
colon cancer prognosis can be derived from gene expression
profile of the primary tumor. Probably, small changes of
different genes in primary tumors are responsible for tumor
progression rather than large changes in only one gene.
Probe sequences in silico hybridization with the human
genome allowed us to confirm the identity of the genes whose
expression was being detected by the probes of our gene
signature: CHD2, RPS5, BRI3, ZNF148, MGC23401
(hypothetical protein), ELK4 and GMEB1 or YTFDH2 would
be down-regulated in relapse and ATPV0A1 up-regulated.
Although most of the probes (5 out of 8) hybridize with exons
of the corresponding genes, two of the probes hybridize with
introns of two well known genes, ATP6V0A1 and ELK4. Our
probe possibly detects a new isoform of these genes in which
the introns would become part of exons by alternative splicing.
Besides, one probe hybridized  only with the intergenic
region between the genes glucocorticoid modulatory element
B1 (GMEB1) and high glucose regulated protein (HGRP8 or
YTHDF2). One of these two genes may present alternative
isoforms that include this probe in an exon, or another gene
still not described could be between these two genes.
CHD2 is one of the most interesting genes in our gene
signature as it has also been related to Dukes' B colon cancer
relapse by an independent group (9) using microarray tech-
nology. The CHD gene family is a group of highly conserved
proteins sharing sequence motifs and functional domains
associated with the regulation of chromatin and gene tran-
scription. It has been recently described that CHD1 specifically
interacts with the methylated lysine 4 mark on histone 3 in
yeast recruiting histone acetylase activity, what is associated
with a remodeling of chromatin that facilitates transcription
(20). On the other hand, CHD1 co-immunoprecipitates with
the transcriptional corepressor NcoR, with histone deacety-
lases and also with RNA splicing proteins (21). Thus, CHD1 is
a key factor in the regulation of transcription by post-
translational modification of histones and also influences
alternative splicing. Some authors suggest that the whole
chromodomain family may have similar recognition properties;
therefore, CHD2 can be expected to participate in the same
or similar processes and its down-regulation may affect
epigenetics and the whole transcription regulation in the cell.
ZNF148 is a zinc finger transcription factor that is
universally expressed (22). It has been shown that ZNF148
binds to GC-rich DNA elements in a variety of promoters
involved in growth regulation (23-25). Moreover, for the rat
pituitary adenoma cell line GH4, Bai and Merchant (26)
showed that elevated expression of ZNF148 inhibits cell pro-
liferation and promotes growth arrest through stabilization of
the p53 protein. Furthermore, tumor cells with a mutation in
the p53 gene are resistant to ZNF148-mediated stabilization
and are associated with hepatocellular carcinoma recurrence
(27). In our study, ZNF148 is down-regulated in patients with
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Figure 3. Real-time PCR analysis of BRI3, CHD2, ZNF148, MGC23401 and RPS5 expression in colon cancer progression. Fifteen samples of Dukes' B (stage II)
and 12 of Dukes' C (stage III) were analyzed. All differences were significant after Mann-Whitney U test.
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relapse and patients with Dukes' C colorectal cancer,
suggesting a deficient stabilization of p53 in the nucleus and
perhaps a deficient growth arrest and higher rates of cell
proliferation.
Ribosomal proteins are highly conserved among eukaryotes
and prokaryotes. RPS5 gene encodes a ribosomal protein that
is a component of the small 40s subunit of ribosomes. There
is recent evidence pointing to extraribosomal functions of
ribosomal proteins. In this regard, recent studies have suggested
a link between ribosomal biogenesis and cell cycle progression.
The molecular mechanism that controls such a link remains
obscure. The involvement of ribosomal proteins in stabilizing
and activating p53 function has been demonstrated (28).
Variable expression of this gene in colorectal cancers
compared to adjacent normal tissues has also been observed
(29), although so far no correlation between the level of
expression and the severity of the disease has been reported. In
this study, we found a lower PRS5 expression in patients
with relapse in comparison with non-relapsed patients.
Moreover, their expression is also down-regulated in Dukes' C
patients in comparison with Dukes' B patients. Additional
research will be required to determine the role of ribosomal
proteins as checkpoints in the carcinogenesis process in general
and of S5 ribosomal protein in colorectal cancer progression.
The BRI3 gene belongs to a family of integral membrane
proteins with broad tissue expression. This protein is
involved in tumor necrosis factor-·-induced cell death in
murine fibrosarcoma cells L929 (30). Its overexpression
induces apoptosis in these cells and the presence of BRI3 is
required in the TNF·-induced cell death. In our study, BRI3
is down-regulated in relapsed patients, suggesting that the
TNF·-induced apoptosis pathway could be altered in colorectal
cancer progression.
Independently of the confirmation of these hypotheses,
our 8 probes for gene expression are able to discriminate
between our relapsed and non-relapsed patients. Furthemore,
in the present study we showed that the down-regulation of
5 out of 8 genes is associated with colon cancer progression.
Thus, a study on the functions of the genes present in this
gene signature could also improve our understanding of the
molecular mechanisms involved in colon cancer progression.
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